← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL VACCINES › Typhoid vaccines
typhoid, purified polysaccharide antigen
J07AP03
Forms & Strengths
- Injectable solution: 25 mcg polysaccharide per 0.5 mL prefilled syringe
- Injectable solution: 25 mcg polysaccharide per 0.5 mL single-dose vial
Adult Dosing
- Primary immunization: 0.5 mL intramuscularly single dose at least 2 weeks prior to potential exposure
- Revaccination: 0.5 mL intramuscularly every 2 years for individuals with continued risk of exposure
Pediatric Dosing
- Children 2 years and older: 0.5 mL intramuscularly single dose at least 2 weeks prior to exposure
- Revaccination in children: 0.5 mL intramuscularly every 2 years if exposure risk persists
Indications
- Active immunization against Salmonella typhi infection
- Recommended for travelers to endemic areas, household contacts of chronic carriers, and laboratory workers
Mechanism of Action
- Induces antibodies against Salmonella typhi Vi polysaccharide capsule
- Stimulates T-cell independent B-cell response providing systemic protection against typhoid fever
Contraindications
- History of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine
- Moderate to severe acute illness with or without fever (defer vaccination until resolution)
Adverse Reactions
- Injection site reactions: pain, erythema, swelling, induration
- Systemic reactions: headache, malaise, fatigue, fever, myalgia, nausea
Drug Interactions
- Immunosuppressive therapies may reduce the immune response to the vaccine
- Can be administered simultaneously with other recommended travel vaccines using separate syringes and injection sites
Curated Content: Needs Vetting Before Put to Clinical Use